Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389530 · ClinicalTrials.gov registry record
Use of Fluorescein Dye for the Removal of Brain Tumors
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 91
- Enrollment target
NCT02389530: Completed study, sponsored by University of Pittsburgh.
NCT02389530 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 91 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02389530 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 91 participants
- Enrollment target
Study Summary
Fluorescein is a dye agent that can be injected through an intravenous line. It has been shown to help tell the difference between brain tumor tissue and normal brain tissue when it is used together with a specialized filter on a microscope in the operating room. The investigators plan to study the use of fluorescein in the removal of brain tumors at a low dose.
Primary Outcome
Assessment of frequency of adverse events related to fluorescein administration, especially anaphylaxis
Interventions
- DRUG Fluorescein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-06 |
What the finished NCT02389530 record still lists
NCT02389530 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 91 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fluorescein is the first listed.
NCT02389530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02389530 about?
NCT02389530 is a clinical study titled "Use of Fluorescein Dye for the Removal of Brain Tumors". Fluorescein is a dye agent that can be injected through an intravenous line. It has been shown to help tell the difference between brain tumor tissue and normal brain tissue when it is used together with a specialized filter on a microscope in the operating room. The investigators plan to study the ...
What is the current status of trial NCT02389530?
This trial is currently completed. The enrollment target is 91 participants. The study started on 2015-05. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02389530?
The interventions under investigation include: Fluorescein (DRUG).
Who is sponsoring clinical trial NCT02389530?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia